Olga Anczuków-Camarda, Ph.D.
Associate Professor
Investigates how alternative RNA splicing contributes to cancer with the goal of identifying novel clinical biomarkers and targets for precision medicine.
My research goal is to elucidate how changes in gene expression regulation contribute to cancer. My lab focuses on characterizing the role of alternative-splicing misregulation in breast and ovarian cancer by using 3D cell culture and PDX models. Our unique expertise in both RNA biology and cancer research allows us to connect these distinct fields, and by combining innovative tools and interdisciplinary approaches, to gain novel insights into the molecular mechanism of gene expression regulation in normal and cancer cells. My research findings should lead to the development of novel biomarkers and promising drugs for cancer therapy.
See a recent article "Splicing factor to blame in triple negative breast cancer" on UCONN Today.
-
Featured ArticleDecember 01, 2022Brooks Scholar Award propels cancer and aging research
Recipients of the 2022 Brooks Scholar Award represent a new generation of scientists whose research bridges the fields of cancer and aging. -
Research HighlightJanuary 26, 2022The consequences of alternative splicing in breast cancer
JAX researchers used long-read mRNA sequencing to catalog all mRNAs in primary breast cancer samples and revealed previously undocumented mRNA isoforms that can change protein function and may contribute to cancer progression and therapy response. -
Research HighlightApril 13, 2021Olga Anczuków seeks to thwart a driver of cancer
JAX Assistant Professor Olga Anczuków, Ph.D., has shed new light on the role of MYC in regulating alternative RNA splicing, a process in which genes called splicing factors enable a single gene to code for multiple unique proteins, or isoforms. -
Press ReleaseAugust 03, 2020Correcting splicing-factor defects in disease
Five-year, $2.1 million federal grant to Olga Anczuków of JAX will reveal the role of splicing-factor defects in cardiac or neurological disorders, cancer, and more.
-
Featured ArticleNovember 22, 2022Understanding cancer-causing MYC and its alternative splicing accomplices
Humans have about 20,000 genes (give or take), far fewer genes than many so-called “primitive” animals, like Daphina pulex, a.k.a. the water flea, which has about 31,000. How then are humans able to be so complex with less genetic material? One answer: alternative splicing. -
Research HighlightDecember 13, 2021Examining the immune response to cancer on a genetic level
The V Foundation for Cancer Research has awarded a grant to JAX's Lucas Chang for genetic studies of the immune response to cancer. -
Research HighlightNovember 10, 2020Alternative RNA splicing: The 'special effects' editing of gene expression
Olga Anczukow describes a network of regulation for splicing factors, key proteins for controlling protein production. Dysfunction can cause a variety of diseases, including cancer. -
Research HighlightDecember 04, 2019Exploring the role of gene splicing in triple negative breast cancer
Splicing factors, comparable to gene editors in our DNA, could hold the key to treating the worst type of breast cancer.